Levin Capital Strategies’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-14,699
Closed -$356K 241
2025
Q2
$356K Sell
14,699
-5,917
-29% -$138K 0.03% 140
2025
Q1
$522K Sell
20,616
-8,217
-28% -$215K 0.06% 109
2024
Q4
$765K Buy
28,833
+5,957
+26% +$162K 0.07% 103
2024
Q3
$662K Buy
22,876
+14,685
+179% +$428K 0.06% 112
2024
Q2
$229K Buy
8,191
+191
+2% +$5.26K 0.02% 183
2024
Q1
$222K Sell
8,000
-71,848
-90% -$1.99M 0.02% 197
2023
Q4
$2.3M Sell
79,848
-90,183
-53% -$2.73M 0.25% 62
2023
Q3
$5.64M Sell
170,031
-13,768
-7% -$487K 0.67% 39
2023
Q2
$6.74M Sell
183,799
-101,859
-36% -$3.96M 0.77% 35
2023
Q1
$11.7M Buy
285,658
+2,494
+0.9% +$108K 1.44% 25
2022
Q4
$14.5M Sell
283,164
-13,594
-5% -$652K 1.95% 15
2022
Q3
$13M Sell
296,758
-47,863
-14% -$2.33M 1.76% 18
2022
Q2
$18.1M Sell
344,621
-14,065
-4% -$717K 2.14% 11
2022
Q1
$18.6M Sell
358,686
-16,254
-4% -$843K 1.79% 17
2021
Q4
$22.1M Sell
374,940
-10,710
-3% -$531K 2.07% 14
2021
Q3
$16.6M Buy
385,650
+3,579
+0.9% +$159K 1.66% 20
2021
Q2
$15M Buy
382,071
+175,459
+85% +$6.82M 1.53% 21
2021
Q1
$7.49M Buy
206,612
+10,699
+5% +$380K 0.8% 32
2020
Q4
$7.21M Sell
195,913
-19,719
-9% -$723K 0.81% 32
2020
Q3
$7.51M Buy
215,632
+14,419
+7% +$506K 0.98% 30
2020
Q2
$6.24M Sell
201,213
-187,261
-48% -$6.36M 0.86% 35
2020
Q1
$12M Sell
388,474
-312,709
-45% -$10.7M 1.94% 17
2019
Q4
$26.1M Sell
701,183
-36,661
-5% -$1.31M 2.6% 12
2019
Q3
$25.2M Sell
737,844
-321,312
-30% -$11.7M 2.78% 10
2019
Q2
$43.5M Buy
1,059,156
+136,503
+15% +$5.42M 4.3% 3
2019
Q1
$37.2M Sell
922,653
-3,687,354
-80% -$148M 4.17% 6
2018
Q4
$191M Sell
4,610,007
-2,124,476
-32% -$88.2M 4.2% 5
2018
Q3
$282M Sell
6,734,483
-187,561
-3% -$7.22M 4.84% 2
2018
Q2
$238M Sell
6,922,044
-551,922
-7% -$18.9M 4.11% 5
2018
Q1
$252M Sell
7,473,966
-2,374,278
-24% -$81.6M 4.58% 2
2017
Q4
$338M Sell
9,848,244
-1,003,927
-9% -$34.2M 5.72% 1
2017
Q3
$368M Buy
10,852,171
+693,867
+7% +$22.3M 6.23% 1
2017
Q2
$324M Buy
10,158,304
+1,224,540
+14% +$38.6M 5.65% 2
2017
Q1
$290M Buy
8,933,764
+172,304
+2% +$5.43M 5.17% 2
2016
Q4
$270M Buy
8,761,460
+500,021
+6% +$15.3M 4.64% 2
2016
Q3
$265K Buy
8,261,439
+1,184,937
+17% +$39.6M 3.9% 3
2016
Q2
$236M Sell
7,076,502
-4,456,802
-39% -$142M 4.26% 5
2016
Q1
$324M Sell
11,533,304
-245,817
-2% -$7.02M 5.87% 1
2015
Q4
$361M Buy
11,779,121
+4,447,343
+61% +$140M 6.34% 1
2015
Q3
$218M Buy
7,331,778
+573,727
+8% +$18.4M 3.73% 3
2015
Q2
$215M Sell
6,758,051
-1,660,879
-20% -$54.1M 3.18% 5
2015
Q1
$278M Sell
8,418,930
-2,673,874
-24% -$85M 4.16% 2
2014
Q4
$328M Buy
11,092,804
+474,149
+4% +$13.6M 4.95% 1
2014
Q3
$298M Buy
10,618,655
+499,716
+5% +$14M 4.53% 1
2014
Q2
$285M Buy
10,118,939
+2,182,146
+27% +$62.2M 4.39% 1
2014
Q1
$242M Sell
7,936,793
-660,546
-8% -$19.7M 4.05% 3
2013
Q4
$250M Sell
8,597,339
-2,800,526
-25% -$81.5M 4.02% 4
2013
Q3
$311M Buy
11,397,865
+1,123,793
+11% +$30.6M 5.3% 1
2013
Q2
$273M Buy
+10,274,072
New +$284M 4.91% 2

Other funds holding PFE

Levin Capital Strategies's PFE Position: Q3 2025 in Review

Levin Capital Strategies sold out of Pfizer (PFE) in Q3 2025, closing a stake of 14,699 shares — an estimated $356K sold.

Levin Capital Strategies first reported a position in PFE in Q2 2013 and held it in 49 quarters. The position peaked at $368M in Q3 2017. 2,812 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • Levin Capital Strategies reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • Levin Capital Strategies sold 14,699 Pfizer shares in Q3 2025, an estimated $356K.
  • Levin Capital Strategies first reported a position in Pfizer in Q2 2013 and held it in 49 quarters.
  • Levin Capital Strategies's Pfizer position peaked at $368M in Q3 2017.
  • 2,812 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Levin Capital Strategies's 13F filing for Q3 2025, filed 7 Nov 2025.